On Q1 2016 Merck Vaccines Sales Growth Stories — Market Share… Matters.

This FiercePharma story has been out for a little over two days.

I generally find that outlet’s reporting to be top notch. I only link to the FiercePharma vaccines item, for a complete record, as I think it suffers from a lack of. . . perspective.

Though closely-guarded as a secret by each of the companies mentioned in the item — in my opinion, market share (the relative position of Kenilworth, compared to the others mentioned, in each vaccine space) explains the bulk of the “trend” described.

That is, one has lots of room to grow at the sales line, when one is a small player — and far less room, when one is nearly the largest, or the largest, player. The more salient question — to my mind — is what’s going on with margins, in each vaccine — by player? That’s my $0.02.


There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: